Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical Policypriority health chelation therapy Coverage Update …
    Ask Trek AI about this page
    Modifiedpriority healthPolicy N/A

    Chelation Therapy Coverage Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Establishes Priority Health coverage criteria, applicable diagnoses, documentation, coding, and prior authorization considerations for chelation therapy; applies to Priority Health members and providers delivering care under covered plans.

    Policy Summary
    Payerpriority health
    PolicyChelation Therapy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMaterial — added non-covered conditions
    Effective DateMar 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation demonstrating medical necessity for chelation therapy; individual case review may be required for exceptions.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Added additional non-covered conditions for chelation therapy.

    New Policy Scope section was added.

    New FDA/Regulatory section was added.

    New Medical/Professional Society Guidelines section was added.

    Policy structure clarified.

    6+medically necessary diagnoses
    4example non-covered conditions
    5CPT/HCPCS codes listed
    MultipleICD-10 groups
    TACT/TACT2major trials cited
    1993-2026document review range

    Coverage Criteria for Chelation Therapy

    Medically Necessary Indications

    Chelation therapy is medically necessary when used to treat ALL of the following diagnoses as listed:

    Medically necessary diagnoses

    • Included diagnoses: a. Biliary cirrhosis; b. Cooley's anemia; c. Cystinuria; d. Heavy metal poisoning (e.g., arsenic, copper, gold, iron, lead, mercury); e. Wilson's disease; f. Patients who have iron overload secondary to multiple blood transfusions (e.g., sickle cell anemia)

      Each listed diagnosis is an acceptable indication

    Not Medically Necessary

    Chelation therapy is considered not medically necessary when used to treat the following conditions:

    Not medically necessary

    • Examples: Autism Spectrum Disorders; Cardiovascular disease (including atherosclerosis, coronary artery disease); Neurodegenerative disorders (Alzheimer's disease or other dementias); Stroke

      List is not exhaustive

    Coverage for chelation therapy is contingent on the member's specific benefits and the applicable plan documents. Group-specific policy or state‑mandated plan documents will supersede this medical policy when applicable. For self‑funded (ASO), individual, HMO/EPO, POS, PPO, Medicare, and Medicaid/Healthy Michigan Plan products, providers should consult the applicable plan or product documents for final coverage determinations; when discrepancies exist, the plan or program rules govern. Providers seeking prior authorization must follow the procedures in the Priority Health Provider Manual and submit documentation demonstrating medical necessity when prior authorization is required.

    The literature and guideline commentaries flag the use of chelation therapy for Autism Spectrum Disorder and for treatment of alleged mercury poisoning without appropriate diagnostic evaluation as unsupported and potentially harmful. Choosing Wisely and specialty toxicology guidance specifically caution against chelation except for documented metal intoxication diagnosed by validated testing, and reviews of autism-related chelation trials note poor quality evidence and safety concerns.

    Use of chelation therapy to treat Autism Spectrum Disorder is not supported by quality evidence and is considered not medically necessary. Professional organizations and systematic reviews advise against routine testing or chelation for autistic behaviors; published case reports and series also document serious adverse events associated with inappropriate chelation in children.

    Chelation therapy for atherosclerotic cardiovascular disease and for neurodegenerative disorders (including Alzheimer's disease) is not proven to improve clinical outcomes in routine practice and is considered not medically necessary. Large trials and systematic reviews (including TACT and TACT2 and multiple reviews) did not demonstrate consistent benefit across populations; some subgroup findings were not replicated and more high‑quality evidence is required before routine use can be recommended.

    Sources cited in this policy identify chelation for Autism Spectrum Disorder and for unproven claims of mercury poisoning as unsupported and potentially inappropriate. Toxicology and clinical practice guidance emphasize that chelating agents should be reserved for documented heavy metal intoxication confirmed by validated biological testing, and that use for unverified mercury exposure or other non‑evidence‑based indications may prompt denial of coverage or safety concerns.

    Relevant Coding

    ICD-10 Codes that may support medical necessityICD-10
    D56.0 - D56.9Thalassemia
    D57.00 - D57.819Sickle-cell disorders
    E72.00 - E72.09Disorders of amino-acid transport
    E83.00 - E83.09Disorders of copper metabolism
    E83.10 - E83.19Disorders of iron metabolism
    E83.52Hypercalcemia
    K74.3Primary biliary cirrhosis
    K74.4Secondary biliary cirrhosis
    K74.5Biliary cirrhosis, unspecified
    T56.0x1A - T56.0x4SToxic effects of lead and its compounds
    1–10 of 19
    1/2
    CPT/HCPCS CodesHCPCS
    J0470Injection, dimercaprol, per 100 mg.
    J0600Injection, edetate calcium disodium, up to 1000 mg.
    J0895Injection, deferoxamine mesylate, 500 mg.
    J3520Edetate disodium, per 150 mg (not covered for Medicaid)
    S9355Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem requires prior auth
    Typical infusion series — inv-10: Typical infusion series
    Typical series lengthApproximately 30 intravenous infusions (delivered weekly or biweekly); individual protocols may vary (example: 40 infusions in TACT2).
    EDTA dose exampleTypical protocol described as 3 g disodium EDTA per infusion delivered in 500–1000 mL normal saline over 1.5–3 hours.
    Adjunctive agents usedConcomitant administration often includes ascorbic acid, B‑vitamins, heparin, and minerals (magnesium, copper, zinc, selenium, manganese).
    Maintenance scheduleAfter initial series, therapy may be followed by a less‑frequent maintenance schedule as clinically indicated.

    Provider Actions, Prior Authorization & Documentation

    Step Therapy

    Stepwise chelation for iron overload

    For iron overload (transfusional or secondary), clinicians should follow a stepwise approach using guideline‑recommended iron chelators. Initiation, selection, and modification of therapy should be based on established indications, iron burden measures, tolerability, and response. Prior authorization and documentation requirements still apply for individual agents or combination regimens.

    • Preferred agents: deferoxamine, deferiprone, deferasirox (select according to age, formulation availability, and adverse-effect profile).
    • Start with monotherapy using an evidence‑based agent appropriate for the patient; escalate to alternative single agents if ineffective or not tolerated.
    • Consider combination regimens (e.g., deferasirox + deferoxamine or deferiprone + deferoxamine) for patients with inadequate response to monotherapy or severe iron burden, supported by clinical evidence.
    • Document baseline iron burden (e.g., serum ferritin trends, liver iron concentration by MRI) and clinical rationale for switching or adding agents.
    • Monitor for drug-specific adverse effects (e.g., agranulocytosis with deferiprone; renal/hepatic toxicity with deferasirox; infusion‑related issues with deferoxamine) and provide laboratory surveillance per product labeling.
    • Provide evidence of prior trials of guideline‑recommended therapy when requesting individual case review or authorization for combination therapy or off‑label regimens.

    Definitions and Protocols

    Chelation therapy — inv-20: Chelation therapy
    DefinitionAdministration of a chelating agent (e.g., EDTA, DMSA, DMPS) to bind heavy metals and facilitate urinary excretion; often involves repeated IV infusions with supportive agents.
    Typical deliveryRepeated intravenous administration of chelating agents (weekly or biweekly in many protocols).
    Primary indicationProven effective for documented heavy metal intoxication and specific diagnoses such as Wilson's disease and transfusional iron overload.
    Evidence limitsNot shown to improve objective outcomes for autism, cardiovascular disease, or neurodegenerative conditions (e.g., Alzheimer’s) per cited reviews and guidelines.
    Typical EDTA protocol — inv-21: Typical EDTA protocol
    EDTA protocol summary

    Background and Evidence Summary

    Chelation refers to administration of agents such as EDTA, DMSA, or DMPS to bind metals and enhance urinary excretion. A commonly cited EDTA regimen involves repeated intravenous infusions—typically a series of approximately 30 infusions of 3 g disodium EDTA with adjunctive vitamins, minerals, and supportive agents delivered over 1.5–3 hours in 500–1000 mL saline, often on a weekly or biweekly schedule. Evidence supports chelation for documented heavy metal intoxication and selected hematologic or genetic conditions that cause iron or copper overload, whereas proposed uses outside these indications lack robust evidence.

    Policy Summary
    Payerpriority health
    PolicyChelation Therapy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMaterial — added non-covered conditions
    Effective DateMar 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation demonstrating medical necessity for chelation therapy; individual case review may be required for exceptions.
    SourceLink
    On This Page
    Coverage Criteria for Chelation TherapyRelevant CodingProvider Actions, Prior Authorization & DocumentationDefinitions and ProtocolsBackground and Evidence Summary
    Series of approximately 30 IV infusions of 3 g disodium EDTA with ascorbic acid, vitamins, heparin, and minerals delivered over 1.5–3 hours in 500–1000 mL normal saline.
    Administration frequencyTypically administered weekly or biweekly, with potential transition to a less frequent maintenance schedule.
    Supportive additivesProtocols commonly include ascorbic acid, B‑vitamins, heparin, and minerals (magnesium, copper, zinc, selenium, manganese).
    Clinical contextDescribed within the background as an example protocol; used in toxicologic and some specialized clinical settings when indicated.
    Chelation therapy — inv-22: Chelation therapy
    Broad definitionAdministration of agents (e.g., EDTA, DMSA, deferoxamine, deferiprone, deferasirox) to bind and promote excretion or redistribution of metals; agents and indications differ across cardiovascular, toxicologic, and hematologic contexts.
    Agent examplesChelators named in the policy include EDTA, DMSA, DMPS, deferoxamine, deferiprone, and deferasirox.
    Indication variabilityIndications vary by agent: toxicologic use for heavy metal poisoning, hematologic use for transfusional iron overload, and investigational/limited evidence for cardiovascular or neurodegenerative indications.
    Evidence noteClinical trial and guideline literature (including iron‑overload trials and cardiovascular reviews) guide agent selection and use; evidence does not support some proposed indications.